Zevra Therapeutics, Inc. ZVRA MIPLYFFA — Revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s miplyffa — revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s MIPLYFFA — revenue, net?
- Zevra Therapeutics, Inc. (ZVRA) reported MIPLYFFA — revenue, net of $24.6M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s MIPLYFFA — revenue, net changed year-over-year?
- Zevra Therapeutics, Inc.'s MIPLYFFA — revenue, net increased by 43.9% year-over-year, from $17.1M to $24.6M.
- What does MIPLYFFA — revenue, net mean?
- This metric represents the total net revenue generated from the sale of the MIPLYFFA therapeutic product after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's commercial adoption and market penetration within the rare disease treatment landscape. Growth in this figure reflects the successful execution of the company's commercialization strategy and the increasing demand for this specific therapy.